Cargando…
Acquired Mechanisms of Resistance to Osimertinib—The Next Challenge
SIMPLE SUMMARY: Osimertinib has revolutionized the treatment of EGFR-mutated tumors. Its current applications include the first-line setting, second-line setting, as well as the adjuvant setting. Although it represents a milestone in the context of targeted therapy, inevitably all tumors develop an...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027936/ https://www.ncbi.nlm.nih.gov/pubmed/35454838 http://dx.doi.org/10.3390/cancers14081931 |